Amir Fathi, MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital. Amir Fathi MD, an esteemed professional at Massachusetts General Hospital in Boston, Massachusetts, recently delivered a noteworthy presentation at a conference. His talk centered on induction strategies within the realm of patients lacking FLT3 mutations, showcasing the breadth of his expertise. The event proved to be a platform for various experts, including Amir’s colleagues, who shared compelling data. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration…
Author: Editor
Alexander Edward Perl, MD, MS is a member of the leukemia program in the Abramson Cancer Center of the University of Pennsylvania and an Associate Professor of Medicine at the Perelman School of Medicine. Alexander E. Perl, MD, MS, an associate professor in the leukemia program at the Abrams Cancer Center, University of Pennsylvania, recently presented at a conference. He discussed identifying resistance mechanisms in FLT3 mutated AML patients and shared data-driven strategies for improved treatment. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/…
Courtney D. DiNardo, MD, MSCE Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Courtney DiNardo, MD, from MD Anderson Cancer Center, discussed IDH inhibitor therapy at a recent conference. She emphasized the benefits of combining IDH inhibitors with other treatments, showcasing a promising triplet therapy involving azacitidine, venetoclax, and IDH inhibitor. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com…
Eytan M. Stein, MD – Leukemia & Early Drug Development Specialist – David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center Eitan M. Stein, MD, Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City, delivered a presentation on the utilization of menin inhibitors in treating acute leukemia. The focus was on their application in patients with KMT2A rearrangements and NPM1 mutations. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/…
Naval G. Daver, MD is an Associate Professor in the Department of Leukemia at MD Anderson Cancer Center. Naval G. Daver, MD, a faculty member at MD Anderson Cancer Center, co-chaired a successful symposium in Houston, Texas, featuring engaging presentations and active participation from junior faculty. Naval’s presentation focused on groundbreaking triplet therapies for acute myeloid leukemia patients unable to undergo intensive chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023…
Brian Andrew Jonas, MD, Ph.D. Associate Professor of Medicine (Clin X) – UC Davis Comprehensive Cancer Center Brian Jonas MD, Ph.D. from U.C. Davis sheds light on the latest advancements in AML treatment, focusing on the practical management of HMA Venetoclax. He delves into standard care approaches, recent progress, dosing adjustments, and toxicity mitigation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Sharing insights from prominent thought leaders at the conference,…
Marina Konopleva, M.D., Ph.D. Professor, Department of Oncology (Medical Oncology) and Department of Molecular Pharmacology Albert Einstein College of Medicine Jack and Pearl Resnick Campus Marina Konopleva, MD, PhD, is a distinguished name in the realm of medical research, serving as the Director of Leukemia at the renowned Einstein Medical Center in New York. With an esteemed cross-appointment at both Ambient’s and Casanthe, Licky Merplatte, Marina Konopleva stands as a prominent authority in the study of leukemia and its intricate treatment mechanisms. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…
Hi Nkem – I just wanted to reach out and introduce myself. I’m Allen Wilbanks here at OncologyTube. It seems our company aligns with Sanofi’s commitment to advancing oncology research and treatments. So I’m leaving my calendar link here: https://meetings.hubspot.com/allen12 Please book a date if you think it would be worth your time to chat. Thank you in advance. Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827
Hi Maria, I’m Allen Wilbanks and I’m taking over all of Scott Nasiff’s accounts here at OncologyTube and I thought I’d reach out and introduce myself. I know you were working with Scott on the Takeda Oncology account last year and from this point forward I’ll be your contact here at OncologyTube. I would love to hear about your new projects so I’m including a link to my calendar here. https://meetings.hubspot.com/allen12 Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827
Hi Frances, Hope you are well. You had reached out to OncologyTube on July 4th and I sent you some initial information about us such as we reach 35,000 HCP per month mainly oncologists and hematologists, in addition you asked us about our geographic reach. I just wanted to reach back out and say hi and ask if you have any more questions? If so please don’t hesitate to book an appointment with me here… https://meetings.hubspot.com/allen12 Cheers, Allen Wilbanks allen@oncologytube.com (951) 326-8827
Breast cancer is a topic that has garnered significant attention over the years, and for good reason. Affecting millions worldwide, it remains one of the most common forms of cancer among women. While early detection and advancements in treatment have improved prognosis for many, metastatic breast cancer (MBC) remains a significant challenge in the oncology world. By definition, metastatic breast cancer is when cancer has spread beyond the breast and axillary lymph nodes to other parts of the body. This form of cancer, often referred to as stage IV breast cancer, necessitates a deeper understanding and exploration of treatment options.…
Hi Dina, just wanted to say and let you know that we just registered for SABCS 2023 so we will be there if you need anything filmed. Also, we are ready whenever you are to launch the video pre-roll campaign or banners. Looking forward to working with you. Cheers, Allen
Farhad Ravandi-Kashani, M.D. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Farhad Ravandi, MD a distinguished professor of medicine at the University of Texas MD Anderson, delivered a captivating presentation on advancing disease assessment in AML patients at a recent conference. Professor Ravandi emphasized the significance of utilizing advanced tools and assays to detect residual leukemia, as emerging data strongly link any remaining leukemia cells to a heightened risk of relapse and poorer outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available -…
Marlise R. Luskin, MD, MSCE is a physician in Dana-Farber’s Adult Leukemia program. Meet Marlise Luskin, MD, MSCE, an esteemed Assistant Professor of Medicine and Senior Physician at Dana-Farber Cancer Institute in Boston, Massachusetts. With a focus on acute lymphoblastic leukemia, Marlise sheds light on the pivotal role of venetoclax in its treatment. Through insightful analysis of preclinical evidence, she explores the drug’s potential sensitivity against the disease, particularly when paired with diverse chemotherapy agents. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS…
Nitin Jain, MD. Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX Nitin Jain, MD delved into the intricacies of T-cell Acute Lymphoblastic Leukemia (T-ALL). He highlighted the pressing medical void in this area and underscored the advent of innovative therapies. In particular, he focused on Chimeric Antigen Receptor T-cell (CAR-T) therapies, which hold immense promise for patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL…
Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD, MSCE discusses novel approaches within the context of CAR T-cell therapy to address the challenge of relapse, which is when cancer returns or resists treatment after an initial response. The two main mechanisms of relapse that she focuses on are loss of persistence (the CAR T cells’ ability to remain effective over time) and antigen modulation (changes in the cancer cells that make them less recognizable to CAR T cells). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US…
Shira N. Dinner, MD. Associate Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Sherra Diner, MD, an esteemed associate professor and leukemia physician at Northwestern University in Chicago, delves into a compelling discussion regarding the treatment of elderly adults with ALS. She emphasizes a departure from conventional chemotherapy approaches, advocating for the adoption of chemo-free and chemo-lite regimens. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Notably, the talk…
Hagop M. Kantarjian, MD. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX In the featured video, renowned expert Hagop Kantarjian, MD, a professor at MD Anderson Cancer Center, delves into groundbreaking developments in the treatment of adult acute lymphoblastic leukemia (ALL). With a focus on cutting-edge strategies, including third-generation TKIs like Ponatinib and Blinatumomab, as well as CD19/CD22-targeting antibodies, Hagop Kantarjian, MD underscores their promising potential to elevate cure rates while diminishing the demand for intensive chemotherapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online…
Tapan M. Kadia, MD. Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX Tapan Kadia, MD, a professor at MD Anderson Cancer Center, discusses acute myeloid leukemia (AML) maintenance therapy at the MD Education Conference. He highlights azacitidine as a standard treatment. After exploring various post-consolidation strategies, hypomethylating agents have emerged, extending remissions after stem cell transplantation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com…
Bijal Shah, MD, MS Hematology/Oncology H. Lee Moffic Cancer Center In the video, Bijal Shah, MD, MS discusses the significance of CAR T-cell therapy in treating B-cell Acute Lymphoblastic Leukemia (B-ALL) at the H. Lee Moffic Cancer Center. Shaw emphasizes the need to integrate CAR T-cell therapy early with novel agents, particularly in low disease burden scenarios, to improve outcomes for adults with B-ALL. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting…
Aaron Logan, MD – Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF) Meet Aaron Logan, MD Associate Professor of Clinical Medicine at the University of California San Francisco, who presented on the use of MRD (Minimal Residual Disease) to guide therapy in adults with acute lymphoblastic leukemia. In the evolving landscape of leukemia treatment, with blinatumomab moving to the forefront and the ECOG nineteen ten study showcasing benefits for patients achieving MRD negativity at the level of ten to the minus four, Aaron highlights the increasing importance of MRD assessment using high sensitivity NGS…
Anjali Advani, MD – Hematology and Medical Oncology – Cleveland Clinic Meet Anjali Ifani, MD the esteemed Director of the Inpatient Leukemia Unit at the renowned Cleveland Clinic. At a recent conference, she delivered an engaging talk on the integration of immunotherapy into front-line therapy for leukemia. Anjali also participated in a lively debate with Dr. Cassidy, focused on the incorporation of Blinatumumab versus Inetuzumab in frontline leukemia therapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX This conference has been an outstanding success, bringing together a diverse and knowledgeable group of experts for engaging discussions and thought-provoking questions. The organization by the MD Education team was seamless and highly professional, and the choice of location was exceptional. Attendees expressed great satisfaction with the faculty’s presentations, which allowed ample time for in-depth discussions, debates, and sharing of viewpoints. The event provided a fantastic platform for networking with colleagues and peers while also benefiting from the expertise of specialists in…
Esophageal adenocarcinoma is a subtype of cancer that arises from the glandular cells in the esophagus, the muscular tube responsible for moving food from the mouth to the stomach. Known to be one of the most aggressive and potentially lethal forms of cancer, esophageal adenocarcinoma has become a major concern in oncology. According to the American Cancer Society, the incidence of this malignancy has been increasing, particularly in Western countries. With a rising prevalence, understanding and addressing esophageal adenocarcinoma become crucial. This involves recognizing the disease’s complexity, from its pathology to the effectiveness of current treatments. An urgent need for…
Dr. Kevin Harrington, Phd of the Royal Marsden Hospital, The Institute of Cancer Research, London, is the author of this OncologyTube.com video. August 5, 2023 Timestamps: 0:29 Why are ipilimumab and nivolumab used together? 0:39 What was the objective of the phase II CheckMate 714 trial? 1:40 How many patients were included in the trial, and what were the inclusion criteria? 3:23 What were the treatment regimens tested in the trial? 4:06 What were the primary endpoints of the trial? 5:33 Did the addition of ipilimumab to nivolumab improve the objective response rate in patients with recurrent or metastatic squamous…
Chronic Lymphocytic Leukemia (CLL), a type of cancer that begins in the bone marrow and invades the blood, is one of the most common adult leukemias. Affecting mainly older adults, it’s a condition that has seen a significant shift in treatment approaches and understanding over the years. CLL is a slow-growing leukemia where the bone marrow makes too many lymphocytes (a type of white blood cell). Unlike acute leukemias, CLL develops gradually and might not cause symptoms for a long time. It can be especially complex to manage in its previously untreated stage, as it may present unique challenges in…
Ann M. Gillenwater, MD – MD Anderson, Department of Head and Neck Surgery, Division of Surgery presents the First Safety and Efficacy Data of the Rakuten Medical Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer at AHNS 2023. Questions: Can you please summarize the Phase 1b/2 study ASP-1929-181 that you presented this week at the American Head & Neck Cancer Society 2023 meeting? Can you please explain the Alluminox technology? Can you provide our viewers with information about any other Alluminox ASP-1929 data in head and neck cancer? Can you talk about…
Barbara Eichhorst, MD Professor of Medicine at UNIVERSITÄTSKLINIKUM KÖLN, is the author of this OncologyTube.com video. Timestamps: 0:09 Can you tell us about the CELL Trial and it´s design and any significant data. 3:04 How many patients were enrolled in the study and what were the characteristics of the patient population? 3:55 Can you touch on any adverse events that were seen in the study? 5:18 What are the common questions you’re asked by your colleagues about this data? 6:59 What are the key takeaways that you’d like to leave are oncologists viewers with and any final thoughts? 7:45 Is…
In this video, Dr. Samuel Klempner, MD summarizes the phase 3 STAR-221 clinical trial investigating a novel treatment for advanced upper gastrointestinal cancers.The STAR-221 study is comparing the combination of the immunotherapies domvanalimab, zimberelimab, and chemotherapy against standard chemotherapy plus nivolumab. It is enrolling over 700 patients with untreated, metastatic gastric, GE junction, or esophageal adenocarcinoma.The co-primary endpoints are progression-free and overall survival. Key secondary endpoints include response rate, duration of response, and safety. Dr. Klempner provides high-level overviews of the preliminary efficacy and safety data from the trial.He also discusses how PD-L1 expression is being analyzed to determine which…
Anju Replacement
Virginia Kaklamani, MD – UT Health San Antonio discusses Elacestrant (ORSERDU), an oral endocrine therapy, has been approved by the FDA for the treatment of advanced or metastatic breast cancer with ESR1-mutations. These mutations are found in up to 40% of tumors in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. A previous analysis showed that patients with ESR1-mut tumors who had prior CDK4/6 inhibitor (CDK4/6i) exposure for at least 12 months experienced a median progression-free survival (PFS) of 8.6 months with elacestrant compared to 1.9 months with standard of care (SOC).A new analysis of the…
Sarbajit Mukherjee, MD, MS, Assistant Professor, Roswell Park Comprehensive Cancer Center conducted a study to investigate the efficacy of a novel treatment approach for localized esophagogastric adenocarcinoma (EGAC). The standard treatment of pre-operative chemoradiation (CRT) followed by surgery leads to a pathologic complete response (pCR) rate of 20%. However, achieving pCR is associated with improved overall survival (OS). In this study, physicians aimed to increase the pCR rate by administering an innovative combination of FTD/TPI and oxaliplatin as induction chemotherapy (IC) prior to standard CRT.Between January 2020 and October 2022, patients eligible for potentially curative surgery with EGAC were enrolled…
Tune in to the 2022 Targeted Therapies Forum to explore the critical role of nutrition in cancer treatment, discussed by leading oncologists Drs. Desai, Khalil, Preeshagul, Luo, and Terri Conneran. This enlightening discussion sheds light on the importance of dietary considerations in managing the side effects and boosting the effectiveness of cancer treatment protocols. The experts delve into practical strategies, evidence-based nutritional interventions, and the latest research findings on the subject, offering valuable insights for healthcare professionals involved in oncology. This invaluable resource is brought to you with support from our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.…
Navigating the world of cancer care requires ample support for patients and their caregivers. In this enlightening video, Dr. Aakash Desai and Terri Conneran share invaluable insights on how to find the essential resources that empower patients and caregivers throughout the cancer treatment journey. Special thanks to our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who make it possible to provide this critical guidance. For more informative videos like this and to join a community of professionals dedicated to improving cancer care, please visit cancerGRACE.org. To engage in conversation with peers and experts in the field, visit…
Opening up to loved ones about a cancer diagnosis is a deeply personal and often challenging experience. In this thought-provoking session, Drs. Preeshagul, Khalil, Luo, and Terri Conneran offer compassionate guidance on how to approach this sensitive conversation. With the generous support from our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, we’re able to bring you this crucial dialogue. Whether you’re facing this situation yourself or supporting someone close to you, we invite you to explore further resources and engage with others who understand your journey. Visit cancerGRACE.org for more, and to join the conversation, visit https://cancergrace.org/forum.
Understanding when to adjust cancer treatment is paramount in patient care. In this crucial session, Drs. Desai, Khalil, and Luo shed light on the indicators, strategies, and considerations that guide the decision to change treatment during cancer progression. Supported by our committed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, this video offers essential insights for patients, caregivers, and healthcare professionals. For further guidance, resources, and community support, please visit cancerGRACE.org. To engage with experts and peers on this vital subject, join the conversation at https://cancergrace.org/forum.
The landscape of treating KRAS+ NSCLC (Non-Small Cell Lung Cancer) is evolving, and understanding how to approach patient care after progression on Sotorasib is vital. In this specialized segment of the 2022 Targeted Therapies Forum, Dr. Jia Luo provides an in-depth examination of therapeutic options for patients who have progressed on Sotorasib. This session is brought to you by our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who enable us to offer invaluable insights to the medical community. For further information on this topic and other related fields in oncology, please visit cancerGRACE.org. To engage with experts,…
Handling the stress associated with cancer scans is a vital aspect of care for both patients and healthcare professionals. In this enlightening session of the 2022 Targeted Therapies Forum, Panelists Conneran, Khalil, Luo, Desai, and Preeshagul shed light on innovative and compassionate methods of stress reduction involving scans. This session is proudly supported by our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who make such essential discussions possible. For more comprehensive information on this topic and to explore a treasure trove of resources related to cancer treatment, care, and therapies, please visit cancerGRACE.org. Join the conversation, share your…
Drs. Khalil, Luo, Desai, and Preeshagul in this insightful video from the 2022 Targeted Therapies Forum as they discuss effective methods for stress reduction involving scans for newly diagnosed patients. Their expert advice offers support, guidance, and practical strategies to ease the emotional toll of diagnosis. Supported by our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, this video is a must-watch for patients, caregivers, and healthcare professionals alike. For more resources and to join the conversation, please visit http://cancerGRACE.org/ or follow the discussion at https://cancergrace.org/forum. Don’t miss the opportunity to learn from leading experts in the field, and…
Dr. Maya Khalil dives into the intricacies of RET+ NSCLC treatments in our 2022 Targeted Therapies Forum. Gain insights as she meticulously compares the efficacy and application of Selpercatinib and Pralsetinib, two leading medications in the field. Supported by our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a deeper understanding and to be a part of the larger conversation on RET+ NSCLC, make sure to visit http://cancerGRACE.org/. Engage with experts and peers in our forum: https://cancergrace.org/forum.”
In the esteemed 2022 Targeted Therapies Forum, Dr. Jia Luo, renowned Medical Oncologist from Dana-Farber Cancer Institute and respected Instructor in Medicine at Harvard, alongside Dr. Isabel Preeshagul, Thoracic Medical Oncologist from Memorial Sloan Kettering, dives deep into the realm of KRAS Treatments and Clinical Trials. Specifically, Dr. Jia Luo sheds light on the treatment pathways for KRAS+ NSCLC and provides insights on navigating the complex landscape of clinical trials. Grateful for the support from our sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To explore more on the latest cancer treatments and engage with a vibrant community, do…
In an inspiring session from the 2022 Targeted Therapies Forum, Terri Conneran, lung cancer survivor and the visionary Founder of KRAS Kickers, shares her profound journey battling KRAS+ NSCLC. Delve into Terri’s story as she unravels the motivation behind establishing KRAS Kickers, a beacon of hope and community for countless others navigating similar health challenges. Special thanks to our valued sponsors for making this enlightening session possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To uncover more insightful stories and groundbreaking discoveries in the world of cancer research, please visit http://cancerGRACE.org/. Engage with experts, survivors, and advocates at https://cancergrace.org/forum.
Dive deep into the world of RET+ NSCLC treatment options with Dr. Maya Khalil, an esteemed Hematology-Oncologist from the Kirklin Clinic of UAB Hospital and an Assistant Professor of Medicine at the University of Alabama at Birmingham. As part of the 2022 Targeted Therapies Forum, Dr. Khalil offers her unparalleled expertise in managing RET Mutated NSCLC, shedding light on the most effective treatments for patients diagnosed with RET+ NSCLC. A heartfelt thank you to our distinguished sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support. Yearning for more? Unlock a treasure trove of insights and groundbreaking…
Join Dr. Maya Khalil, renowned Hematology-Oncologist from Kirklin Clinic of UAB Hospital and Assistant Professor at the University of Alabama at Birmingham, as she delves into the intricate realm of RET+ NSCLC. In this exclusive segment from the 2022 Targeted Therapies Forum, Dr. Khalil demystifies the processes behind detecting RET mutations and offers insights into the typical profiles of patients who carry these mutations. A big shoutout to our prestigious sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for backing this endeavor. Hungry for more cutting-edge discussions and breakthroughs in the field of oncology? Make sure to explore http://cancerGRACE.org/.…
Delve deep into the world of RET+ NSCLC with Dr. Maya Khalil, a distinguished Hematology-Oncologist from the Kirklin Clinic of UAB Hospital and an Assistant Professor at the University of Alabama at Birmingham. In this revealing segment from the 2022 Targeted Therapies Forum, Dr. Khalil offers an illuminating case study of a patient she treated, shedding light on the intricacies of RET+ NSCLC and the complexities of gene alterations. We extend our gratitude to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support. Eager to dive deeper into oncology’s evolving landscape? Make your way…
Unveiling the latest insights on KRAS+ NSCLC, join Dr. Jia Luo, an esteemed Medical Oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard, in this riveting session from the 2022 Targeted Therapies Forum. Dr. Luo delves deep into the nuances of managing KRAS Mutated NSCLC, exploring state-of-the-art treatment strategies to benefit patients diagnosed with KRAS+ NSCLC. A special thank you to our generous sponsors for their support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological advancements. Dive deeper into our resources at http://cancerGRACE.org/. Engage with pioneers in the field and be…
Decoding the complexities of biopsies for KRAS+ NSCLC, join Dr. Jia Luo, a prominent Medical Oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard, in this informative session from the 2022 Targeted Therapies Forum. With an in-depth look into KRAS Mutated NSCLC management, Dr. Luo specifically shines a light on the various biopsy types crucial for KRAS diagnosis. Heartfelt gratitude to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a broader spectrum of resources and insights in the realm of oncology, visit http://cancerGRACE.org/. Join our vibrant community and engage…
Demystifying treatment timelines for KRAS+ NSCLC, the 2022 Targeted Therapies Forum presents Dr. Jia Luo, an esteemed Medical Oncologist from Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard. Dive deep into the intricacies of KRAS Mutated NSCLC management as Dr. Luo meticulously outlines the treatment timelines for patients diagnosed with KRAS+ NSCLC in this enlightening English edition. A massive shoutout to our revered sponsors who have been instrumental in bringing this knowledge to you: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Expand your horizons in oncological treatments and breakthroughs by visiting http://cancerGRACE.org/. Engage, inquire, and connect with…
Explore the landscape of KRAS+ NSCLC treatment in the 2022 Targeted Therapies Forum with Dr. Jia Luo, a distinguished Medical Oncologist from Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard. In this enlightening video, Dr. Luo delves into the prevalence of KRAS+ NSCLC and charts the transformative journey of its treatments over the years. Special thanks to our invaluable sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay informed with the latest in oncology research and insights. Visit http://cancerGRACE.org/ and become an active part of our thriving community at https://cancergrace.org/forum.
Dive deep into the world of Next-Generation Sequencing (NGS) tests in our 2022 Targeted Therapies Forum’s breakout session. Esteemed oncologists Dr. Seetharamu and Dagogo-Jack elucidate the contrasts between RNA and DNA testing methodologies for NSCLC. Unravel the intricacies, advantages, and clinical implications of each method, providing clinicians and patients with a clearer perspective on these critical diagnostic tools. We extend our gratitude to our steadfast sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological advancements. Visit http://cancerGRACE.org/ and engage in insightful discussions at https://cancergrace.org/forum.